Aims: A soluble form of endoglin (sEng) was proposed to participate in the induction of endothelial dysfunction in small blood vessels. Here, we tested the hypothesis that high levels of sEng combined with a high-fat diet induce endothelial dysfunction in an atherosclerosis-prone aorta. Methods and Results: Six-month-old female and male transgenic mice overexpressing human sEng (Sol-Eng+) with low (Sol-Eng+low) or high (Sol-Eng+high) levels of plasma sEng were fed a high-fat rodent diet containing 1.25% cholesterol and 40% fat for 3 months. The plasma cholesterol and mouse sEng levels did not differ in the Sol-Eng+high and Sol-Eng+low mice. The expression of proinflammatory (P-selectin, ICAM-1, pNFκB and COX-2) and oxidative-stress-related markers (HO-1, NOX-1 and NOX-2) in the aortas of Sol-Eng+high female mice was significantly higher than in Sol-Eng+low female mice. Endothelium-dependent vasodilatation induced by acetylcholine was preserved better in the Sol-Eng+high female mice than in the Sol-Eng+low female mice. Conclusion: These results suggest that high concentrations of sEng in plasma in combination with a high-fat diet induce the simultaneous activation of proinflammatory, pro-oxidative and vasoprotective mechanisms in mice aorta and the balance of these biological processes determines whether the final endothelial phenotype is adaptive or maladaptive.

Keywords:
Soluble endoglin, Endothelial dysfunction, Vascular contractility, Mice
1.
Lopez-Novoa JM, Bernabeu C: The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010;299:H959-H974.
2.
Nachtigal P, Zemankova Vecerova L, Rathouska J, Strasky Z: The role of endoglin in atherosclerosis. Atherosclerosis 2012;224:4-11.
3.
Ikemoto T, Hojo Y, Kondo H, Takahashi N, Hirose M, Nishimura Y, Katsuki T, Shimada K, Kario K: Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels 2012;27:344-351.
4.
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649.
5.
Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P: Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 2010;70:4141-4150.
6.
Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, Martinez-Salgado C: Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010;8:86.
7.
Blann AD, Wang JM, Wilson PB, Kumar S: Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 1996;120:221-226.
8.
Strasky Z, Vecerova L, Rathouska J, Slanarova M, Brcakova E, Kudlackova Z, Andrys C, Micuda S, Nachtigal P: Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ J 2011;75:1747-1755.
9.
Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V: Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis 2008;197:264-270.
10.
Walshe TE, Dole VS, Maharaj AS, Patten IS, Wagner DD, D'Amore PA: Inhibition of VEGF or TGF-β signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol 2009;29:1185-1192.
11.
Valbuena-Diez AC, Blanco FJ, Oujo B, Langa C, Gonzalez-Nunez M, Llano E, Pendas AM, Diaz M, Castrillo A, Lopez-Novoa JM, Bernabeu C: Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation 2012;126:2612-2624.
12.
Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P: High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS One 2015;10:e0119665.
13.
Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:III27-III32.
14.
Najemnik C, Sinzinger H, Kritz H: Endothelial dysfunction, atherosclerosis and diabetes. Acta Med Austriaca 1999;26:148-153.
15.
Shaul PW: Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 2003;547:21-33.
16.
Dong X, Li D, Liu H, Zhao Y: SOD3 and eNOS genotypes are associated with SOD activity and NO. Exp Ther Med 2014;8:328-334.
17.
Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, Rodriguez-Barbero A, Bernabeu C, Lopez-Novoa JM: Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004;18:609-611.
18.
Jerkic M, Rodriguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Wang A, Perez-Barriocanal F, Arevalo M, Bernabeu C, Letarte M, Lopez-Novoa JM: Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res 2006;69:845-854.
19.
Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M: A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005;96:684-692.
20.
Rathouska J, Vecerova L, Strasky Z, Slanarova M, Brcakova E, Mullerova Z, Andrys C, Micuda S, Nachtigal P: Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res 2011;64:53-59.
21.
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, Group CS: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
22.
Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990;265:8361-8364.
23.
St-Jacques S, Cymerman U, Pece N, Letarte M: Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology 1994;134:2645-2657.
24.
Garcia-Prieto CF, Hernandez-Nuno F, Rio DD, Ruiz-Hurtado G, Aranguez I, Ruiz-Gayo M, Somoza B, Fernandez-Alfonso MS: High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. Mol Nutr Food Res 2015;59:520-532.
25.
Seven A, Guzel S, Seymen O, Civelek S, Bolayirli M, Yigit G, Burcak G: Nitric oxide synthase inhibition by L-NAME in streptozotocin induced diabetic rats: impacts on oxidative stress. Tohoku J Exp Med 2003;199:205-210.
26.
Gerhardt T, Ley K: Monocyte trafficking across the vessel wall. Cardiovasc Res 2015;107:321-330.
27.
Drummond GR, Sobey CG: Endothelial NADPH oxidases: which NOX to target in vascular disease? Trends Endocrinol Metab 2014;25:452-463.
28.
Lee KP, Sudjarwo GW, Jung SH, Lee D, Lee DY, Lee GB, Baek S, Kim DY, Lee HM, Kim B, Kwon SC, Won KJ: Carvacrol inhibits atherosclerotic neointima formation by downregulating reactive oxygen species production in vascular smooth muscle cells. Atherosclerosis 2015;240:367-373.
29.
Manea A: NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 2010;342:325-339.
30.
Scheschowitsch K, Moraes JA, Sordi R, Barja-Fidalgo C, Assreuy J: Rapid NOS-1-derived nitric oxide and peroxynitrite formation act as signaling agents for inducible NOS-2 expression in vascular smooth muscle cells. Pharmacol Res 2015;100:73-84.
31.
Dimmeler S, Dernbach E, Zeiher AM: Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000;477:258-262.
32.
Lund DD, Gunnett CA, Chu Y, Brooks RM, Faraci FM, Heistad DD: Gene transfer of extracellular superoxide dismutase improves relaxation of aorta after treatment with endotoxin. Am J Physiol Heart Circ Physiol 2004;287:H805-H811.
33.
Iida S, Chu Y, Francis J, Weiss RM, Gunnett CA, Faraci FM, Heistad DD: Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure. Am J Physiol Heart Circ Physiol 2005;289:H525-H532.
34.
Foresman EL, Miller FJ, Jr: Extracellular but not cytosolic superoxide dismutase protects against oxidant-mediated endothelial dysfunction. Redox Biol 2013;1:292-296.
35.
Araujo JA, Zhang M, Yin F: Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol 2012;3:119.
36.
Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, Nabel EG: Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001;7:693-698.
37.
Kajimura M, Shimoyama M, Tsuyama S, Suzuki T, Kozaki S, Takenaka S, Tsubota K, Oguchi Y, Suematsu M: Visualization of gaseous monoxide reception by soluble guanylate cyclase in the rat retina. FASEB J 2003;17:506-508.
38.
Maulik N, Engelman DT, Watanabe M, Engelman RM, Rousou JA, Flack JE 3rd, Deaton DW, Gorbunov NV, Elsayed NM, Kagan VE, Das DK: Nitric oxide/carbon monoxide. A molecular switch for myocardial preservation during ischemia. Circulation 1996;94:II398-II406.
39.
Wu L, Wang R: Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 2005;57:585-630.
40.
Nachtigal P, Vecerova L, Pospisilova N, Micuda S, Brcakova E, Navarro Hernandez E, Pospechova K, Semecky V: Endoglin co-expression with eNOS, SMAD2 and phosphorylated SMAD2/3 in normocholesterolemic and hypercholesterolemic mice: an immunohistochemical study. Histol Histopathol 2009;24:1499-1506.
41.
Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, Lopez-Novoa JM, Attisano L, Bernabeu C: Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 2007;210:456-468.
42.
Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP: Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000;153:323-335.
43.
Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, Groux H: Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003;102:4052-4058.
44.
Redondo S, Santos-Gallego CG, Tejerina T: TGF-β1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev 2007;18:279-286.
45.
Saura M, Zaragoza C, Cao W, Bao C, Rodriguez-Puyol M, Rodriguez-Puyol D, Lowenstein CJ: Smad2 mediates transforming growth factor-β induction of endothelial nitric oxide synthase expression. Circ Res 2002;91:806-813.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.